Skip to main content

RETINOL SUPPLEMENTATION REDUCES MELANOMA RISK IN WOMEN

Image result for RETINOL SUPPLEMENTATION REDUCES MELANOMA RISK IN WOMEN

Taking daily vitamin A supplements could protect against deadly melanoma skin cancer, scientists claim.
According to researchers from the Kaiser Permanente Northern California Division of Research, a compound found in vitamin A, (Retinol), is vital for protecting against skin cancer.
Retinol is part of a family of chemical compounds known as retinoids and penetrates the outer layers of the skin and repairs damage to the lower layers, where collagen and elastin are found.
Acid found in Retinol encourages skin cells to function normally and increases regular cell renewal. It is also widely praised for its anti-aging properties.
Expert dermatologists analyzed the skin cancer risk in 69,635 men and women aged between 50 and 76 who took a daily vitamin A supplement, either through a pill form or as food supplements.
Researchers discovered that those who took the supplements, in particular, retinol, were 60% less likely to develop melanoma skin cancer, the deadliest form, than those who took no supplements. Participants who took higher does of more than 1,200mg a day, increased their prevention against cancer by 74%.
Interestingly, researchers found no link between foods containing vitamin A (like eggs, liver, and milk) and a reduced risk of skin cancer, as well as another powerful compound that the body turns into vitamin A (carotenoids).
Carotenoids, commonly found in bright colored vegetables like carrots and tomatoes, are said to improve the immune system and contain powerful antioxidants.
Researchers discovered that vitamin A retinol supplements had the biggest impact on women.
Dr. Maryam Asgari, a dermatologist from the study, said, as reported on the Daily Mail: “Our data suggest a possible interaction between supplemental retinol use and the anatomic site of melanoma, with sun-exposed sites showing a stronger protective effect than sun-protected sites.”
However, a leading cancer charity has warned people against bulk buying retinol supplements.
Claire Knight, senior health information officer at Cancer Research UK, told The Huffington Post: “We don’t recommend people start taking retinol supplements based on this study, particularly at high doses can be toxic.
“The result was based on a very small number of people with melanoma, and the authors didn’t account for other important factors that influence the risk of skin cancer, such as the number of moles a person has.
“And crucially, when the authors looked at whether a particular dose was linked to risk, the link between retinol and melanoma disappeared.
“The good news is that you can reduce the risk of skin cancer by enjoying the sun safely – use shade, clothing and at least SPF 15 sunscreen to help protect your skin from sunburn.”

Comments

Post a Comment

Popular posts from this blog

HYFRECATORS AND INTERFERENCE WITH IMPLANTABLE CARDIAC DEVICES

Investigation of Hyfrecators and They are In Vitro Interference with Implantable Cardiac Devices CHRISTOPHER WEYER, DO,* RONALD J. SIEGLE, MD,†‡ AND GUILLAUME GIRARD P. ENG, EMI-EMC§ BACKGROUND Guidelines exist for minimizing potential electromagnetic interference (EMI) with electrosurgical equipment in patients with cardiac rhythm management (CRM) devices. These guidelines encompass all electrosurgical devices but are not specific for hyfrecators. OBJECTIVE To investigate the potential interference of CRM devices by hyfrecators. MATERIALS AND METHODS Using a collagen-based saline gel, three implantable pulse generators (pacemakers) and three implantable cardioverter defibrillators were tested to measure the EMI from two commonly used hyfrecators. The six devices were tested using the hyfrecator under normal use settings and on maximum power. RESULTS Hyfrecators did not interfere with defibrillators and affected pacemakers only when used in close proximity to the devi...
Post a Comment
Read more

NEW DRUG THERAPY FOR BCC

Genentech Submits New Drug Application to FDA for Vismodegib for Rare Form of Advanced Skin Cancer Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate. Vismodegib is an investigational, oral, targeted medicine designed to selectively inhibit signaling in the Hedgehog pathway, which is implicated in more than 90 percent of BCC cases. BCC is the most common type of skin cancer, which is generally considered curable by surgery. However, when it advances, BCC can cause disfiguring and debilitating effects and can ultimately be life-threatening. “We are excited by the pivotal study results that showed vismodegib substantially reduced tumor size or healed lesions for people with this rare skin cancer, which has no approved ...
Post a Comment
Read more

TRANSACTION AND MELANOMA SURVIVAL

The rate of melanoma transaction with various biopsy techniques and the influence of tumor transaction on patient survival Mohsin Mir, MD, C. Stanley Chan, MD, Farhan Khan, MD, MBA, Bhuvaneswari Krishnan, MD, Ida Orengo, MD, and Theodore Rosen, MD Houston, Texas Background: Depth of melanoma invasion is critical because it dictates patient treatment and prognosis. Recent reports indicate melanoma transection with initial biopsy does not impact patient survival; however, tumor transaction can lead to misdiagnosis and inaccurate staging. Objective: This study assessed the rate of melanoma transaction with various biopsy techniques and the impact of tumor transaction on patient survival. Methods: We conducted a retrospective review of all melanoma cases at our institution between 2000 and 2008. Of the 490 melanoma cases identified, 479 met inclusion criteria for the study. The transaction rates of biopsy techniques were determined. Cases of transected ...
Post a Comment
Read more